Biotech news that matter for investors: Opko Health Inc. (NYSE:OPK), ImmunoGen, Inc. (NASDAQ:IMGN)


Opko Health Inc. (NYSE:OPK) lost 2.04% by the end of recent close at $ 9.74. The percentage change in the price over the last fifty two weeks remained -43.64%. The price range in those 52 weeks had a highest hit of $ 19.20 while lowest level in that period was $ 7.12. Latest closing price was -7.65% above its 50-day moving average and -4.80% below its 200-day moving average.

On May 11, 2016 Opko Health, Inc. (OPK) announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE®.

Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO, Dr. Laidlaw served as Relypsa’s Executive Director, Medical Affairs, and Sanofi’s National Director, Medical Science Liaisons, Medical Affairs.

Shares of ImmunoGen, Inc. (NASDAQ:IMGN) traded up 2.17% in last trading session to close the session at a price $ 5.64 share.  With an average trading capacity of 1.26M shares, the number of shares traded in most recent session was 1,201,500 shares. Its previous 52-week high was $ -70.97 and moved down 3.87% over the same period, currently having a market cap around $ 490.88M. Shares have added -55.45% over the trailing 6 months. The stock presently trades -30.01% below its SMA 50 and -47.91% below its SMA 200.

On May 11, 2016 ImmunoGen, Inc. (IMGN) announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • UBS Global Healthcare Conference
    9:00 am ET, May 25, 2016
  • Jefferies 2016 Healthcare Conference
    10:00 am ET, June 9, 2016

The webcasts will be accessible live through the “Investors” section of the Company’s website,; a replay will be available at the same location for approximately a week.